Curtis Advisory Group Adds Amgen Shares to Portfolio

Investment firm discloses new position in biotech giant Amgen Inc.

Apr. 12, 2026 at 8:28am

Got story updates? Submit your updates here. ›

A dramatic, macro-level view of the intricate, industrial-scale equipment and components found inside a modern biotech research laboratory, conveying a sense of the sophisticated technology and processes behind pharmaceutical innovation.The investment in Amgen by Curtis Advisory Group underscores the institutional interest in the biotech industry's complex, high-tech infrastructure.Thousand Oaks Today

Curtis Advisory Group LLC, a financial advisory firm, disclosed in a recent SEC filing that it purchased 5,100 shares of Amgen Inc. (NASDAQ: AMGN) during the fourth quarter. The new position in the biotech company's stock is valued at approximately $1.67 million.

Why it matters

Amgen is one of the world's largest independent biotechnology companies, with a focus on developing innovative human therapeutics. The investment by Curtis Advisory Group signals confidence in Amgen's long-term growth potential and the firm's belief that the stock is undervalued.

The details

According to the 13F filing, Curtis Advisory Group established a new position in Amgen during the fourth quarter of 2025. The firm purchased 5,100 shares of the biotech company's stock, which was valued at around $1.67 million based on Amgen's share price at the time.

  • Curtis Advisory Group filed the 13F disclosure on April 12, 2026, reporting its Q4 2025 holdings.

The players

Curtis Advisory Group LLC

A financial advisory firm that manages investments and provides wealth management services.

Amgen Inc.

A global biotechnology company that focuses on developing innovative human therapeutics to address serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

The investment by Curtis Advisory Group in Amgen reflects the firm's belief in the long-term growth potential of the biotech industry and Amgen's position as a leading player in the sector. This move could signal increased institutional interest in Amgen's stock as the company continues to develop its pipeline of innovative therapies.